VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.08), FiscalAI reports. The company had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.40 million. During the same period in the prior year, the firm posted ($1.67) EPS.
VistaGen Therapeutics Trading Down 0.6%
Shares of NASDAQ:VTGN opened at $0.57 on Tuesday. The firm has a market cap of $22.70 million, a P/E ratio of -0.30 and a beta of 0.31. VistaGen Therapeutics has a twelve month low of $0.43 and a twelve month high of $5.14. The company has a 50 day moving average of $0.60 and a 200-day moving average of $1.01.
Analysts Set New Price Targets
A number of analysts recently weighed in on VTGN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Wednesday, June 3rd. Wall Street Zen cut shares of VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Four equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $0.95.
Institutional Investors Weigh In On VistaGen Therapeutics
Large investors have recently modified their holdings of the stock. Luminus Management LLC purchased a new stake in shares of VistaGen Therapeutics during the fourth quarter valued at $232,000. Two Sigma Investments LP increased its stake in VistaGen Therapeutics by 223.5% in the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock worth $1,027,000 after purchasing an additional 199,958 shares in the last quarter. Millennium Management LLC raised its holdings in VistaGen Therapeutics by 853.0% during the 4th quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock worth $130,000 after buying an additional 176,369 shares during the period. OMERS ADMINISTRATION Corp purchased a new stake in VistaGen Therapeutics during the fourth quarter valued at about $68,000. Finally, Jane Street Group LLC acquired a new position in shares of VistaGen Therapeutics in the second quarter worth about $190,000. 78.39% of the stock is owned by institutional investors.
VistaGen Therapeutics Company Profile
VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.
The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.
Featured Articles
- Five stocks we like better than VistaGen Therapeutics
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
